Shares of Orthofix International NV (NASDAQ:OFIX) fell 1.9% during trading on Friday . The stock traded as low as $44.98 and last traded at $45.85, with a volume of 64,414 shares trading hands. The stock had previously closed at $46.75.

Several brokerages have commented on OFIX. Zacks Investment Research cut shares of Orthofix International NV from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 4th. TheStreet upgraded shares of Orthofix International NV from a “hold” rating to a “buy” rating in a research report on Monday, May 2nd.

The company’s 50 day moving average price is $44.88 and its 200-day moving average price is $41.68. The stock has a market capitalization of $840.04 million and a price-to-earnings ratio of 91.25.

Orthofix International NV (NASDAQ:OFIX) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.13. The firm earned $98.70 million during the quarter, compared to the consensus estimate of $93.10 million. The business’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business earned ($0.15) earnings per share. On average, equities analysts expect that Orthofix International NV will post $1.35 earnings per share for the current year.

In other Orthofix International NV news, CEO Brad Mason sold 18,336 shares of the firm’s stock in a transaction that occurred on Thursday, June 9th. The shares were sold at an average price of $46.00, for a total value of $843,456.00. Following the sale, the chief executive officer now owns 160,256 shares in the company, valued at $7,371,776. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Maria Sainz sold 4,157 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $46.33, for a total transaction of $192,593.81. Following the completion of the sale, the director now owns 20,828 shares in the company, valued at approximately $964,961.24. The disclosure for this sale can be found here.

Other hedge funds recently modified their holdings of the company. Russell Frank Co raised its stake in shares of Orthofix International NV by 80.3% in the fourth quarter. Russell Frank Co now owns 43,978 shares of the medical device company’s stock worth $1,741,000 after buying an additional 19,582 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Orthofix International NV by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 34,774 shares of the medical device company’s stock worth $1,363,000 after buying an additional 600 shares in the last quarter. Teton Advisors Inc. raised its stake in shares of Orthofix International NV by 7.1% in the fourth quarter. Teton Advisors Inc. now owns 45,200 shares of the medical device company’s stock worth $1,772,000 after buying an additional 3,000 shares in the last quarter. Gabelli Funds LLC raised its stake in shares of Orthofix International NV by 0.7% in the fourth quarter. Gabelli Funds LLC now owns 279,450 shares of the medical device company’s stock worth $10,957,000 after buying an additional 2,000 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Orthofix International NV by 18.3% in the fourth quarter. GSA Capital Partners LLP now owns 42,609 shares of the medical device company’s stock worth $1,671,000 after buying an additional 6,601 shares in the last quarter.

Orthofix International N.V. (Orthofix) is a diversified, global medical device company focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians across the world. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.